Newsfiscal.ai
Anika Therapeutics Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
· Published
Article summary
Anika Therapeutics announced 10% year-over-year revenue growth for the third quarter of 2026 and raised its full-year 2026 revenue and adjusted EBITDA guidance.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…